In a welcome move, Castle Biosciences saw its Relative Strength Rating rise from 65 to 77 on Tuesday.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique rating tracks share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an 80 or better RS Rating as they launch their biggest runs. See if Castle Biosciences can continue to show renewed price strength and hit that benchmark.
Castle Biosciences is not currently near a potential buy zone. See if the stock goes on to form a promising consolidation that could kick off a new price move.
The company posted negative growth for both sales and earnings last quarter.
The company earns the No. 19 rank among its peers in the Medical-Services industry group. GeneDx Holdings, InfuSystem Holdings and Hims & Hers Health are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
